GoAI
Get started
POMDOCTOR Ltd logo

POMDOCTOR Ltd

POM

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$0.9501

−$0.07 · -6.86%

Aug 21, 4:00 PM ET

POM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

73

Undervalued

Momentum

17

Strong Down

Sentiment

46

Mixed

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Zhenyang Shi
Listed since
Oct 8, 2025
Employees
165

Market position

Day range

Current $0.9501

52-week range

Current $0.9501

Open
$1.0361
Previous close
$1.0201
Volume
4.57K
0.01× average
Average volume
326.22K
Average daily volume
Market cap
6.44M USD
Beta
2.28
Market reference 1
50-day average
$1.1726
-18.98% below average
200-day average
$14.2115
-93.31% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.74×
P/B (TTM)
-0.82×
P/S (TTM)
0.11×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
13.07%
Operating margin
-29.10%
Net margin
-53.16%

Financial health

Debt / equity
-1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends36%-9%-54%-99%Gross margin, FY2021: 24.38%Gross margin, FY2022: 22.37%Gross margin, FY2023: 12.70%Gross margin, FY2024: 13.92%Gross margin, FY2025: 13.07%Operating margin, FY2021: -36.99%Operating margin, FY2022: -1.47%Operating margin, FY2023: -7.30%Operating margin, FY2024: -7.53%Operating margin, FY2025: -29.10%Net margin, FY2021: -87.47%Net margin, FY2022: -51.18%Net margin, FY2023: -47.69%Net margin, FY2024: -41.85%Net margin, FY2025: -53.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 24.38%. Gross margin FY2022 22.37%. Gross margin FY2023 12.70%. Gross margin FY2024 13.92%. Gross margin FY2025 13.07%. Operating margin FY2021 -36.99%. Operating margin FY2022 -1.47%. Operating margin FY2023 -7.30%. Operating margin FY2024 -7.53%. Operating margin FY2025 -29.10%. Net margin FY2021 -87.47%. Net margin FY2022 -51.18%. Net margin FY2023 -47.69%. Net margin FY2024 -41.85%. Net margin FY2025 -53.16%.

Income trends

Revenue

399.91M USD+16.74%

Operating income

−116.37M USD-351.21%

Net income

−212.58M USD-48.28%
Income trends across reported periods461.16M USD216.17M USD−28.83M USD−273.83M USDRevenue, FY2021: 215.38M USDRevenue, FY2022: 245.22M USDRevenue, FY2023: 304.85M USDRevenue, FY2024: 342.56M USDRevenue, FY2025: 399.91M USDOperating income, FY2021: −79.67M USDOperating income, FY2022: −3.59M USDOperating income, FY2023: −22.25M USDOperating income, FY2024: −25.79M USDOperating income, FY2025: −116.37M USDNet income, FY2021: −188.4M USDNet income, FY2022: −125.51M USDNet income, FY2023: −145.39M USDNet income, FY2024: −143.36M USDNet income, FY2025: −212.58M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 215.38M USD. Revenue FY2022 245.22M USD. Revenue FY2023 304.85M USD. Revenue FY2024 342.56M USD. Revenue FY2025 399.91M USD. Operating income FY2021 −79.67M USD. Operating income FY2022 −3.59M USD. Operating income FY2023 −22.25M USD. Operating income FY2024 −25.79M USD. Operating income FY2025 −116.37M USD. Net income FY2021 −188.4M USD. Net income FY2022 −125.51M USD. Net income FY2023 −145.39M USD. Net income FY2024 −143.36M USD. Net income FY2025 −212.58M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue399.91M USD342.56M USD304.85M USD245.22M USD215.38M USD
Cost of goods sold347.63M USD294.86M USD266.13M USD190.36M USD162.88M USD
Gross profit52.28M USD47.69M USD38.72M USD54.86M USD52.51M USD
Research and development12.86M USD3M USD3.37M USD3.59M USD4.28M USD
Selling, general, and administrative155.94M USD68.24M USD55.99M USD54.87M USD102.95M USD
Operating expenses168.66M USD73.49M USD60.97M USD58.46M USD132.18M USD
Interest expense12.89M USD12.96M USD13.85M USD16.02M USD16.29M USD
Depreciation and amortization149.31K USD134.51K USD112.09K USD—21.32M USD
Operating income−116.37M USD−25.79M USD−22.25M USD−3.59M USD−79.67M USD
Net income−212.58M USD−143.36M USD−145.39M USD−125.51M USD−188.4M USD

Company facts updated Aug 24, 2026.

Corporate actions

Corporate action history

Stock split

Effective Jun 22, 2026

1:18

POM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research POM

research.disclaimer